LAB B Stock Overview
Provides pharmaceutical and personal care products primarily in Latin America. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
My Notes
Capture your thoughts, links and company narrative
Genomma Lab Internacional, S.A.B. de C.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | Mex$25.78 |
| 52 Week High | Mex$28.39 |
| 52 Week Low | Mex$12.39 |
| Beta | 0.48 |
| 1 Month Change | -1.98% |
| 3 Month Change | 24.78% |
| 1 Year Change | 90.68% |
| 3 Year Change | 18.15% |
| 5 Year Change | 34.27% |
| Change since IPO | 214.77% |
Recent News & Updates
Recent updates
Investors Appear Satisfied With Genomma Lab Internacional, S.A.B. de C.V.'s (BMV:LABB) Prospects
Dec 02
Genomma Lab Internacional. de (BMV:LABB) Has A Pretty Healthy Balance Sheet
Oct 17Calculating The Intrinsic Value Of Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB)
Sep 11With Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) It Looks Like You'll Get What You Pay For
Jul 12These 4 Measures Indicate That Genomma Lab Internacional. de (BMV:LABB) Is Using Debt Reasonably Well
May 31Here's Why Genomma Lab Internacional. de (BMV:LABB) Can Manage Its Debt Responsibly
Jan 29Is Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) Trading At A 49% Discount?
Nov 07Is Genomma Lab Internacional. de (BMV:LABB) Using Too Much Debt?
Mar 31Is Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) Trading At A 32% Discount?
Feb 24Does Genomma Lab Internacional. de (BMV:LABB) Have A Healthy Balance Sheet?
Dec 07Rainbows and Unicorns: Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) Analysts Just Became A Lot More Optimistic
Sep 24Analysts Just Made A Major Revision To Their Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) Revenue Forecasts
Aug 01Genomma Lab Internacional. de (BMV:LABB) Has A Pretty Healthy Balance Sheet
Jul 27Here's Why Genomma Lab Internacional. de (BMV:LABB) Can Manage Its Debt Responsibly
Mar 22Are Investors Undervaluing Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) By 44%?
Feb 15Genomma Lab Internacional. de (BMV:LABB) Seems To Use Debt Quite Sensibly
Nov 24Here's Why I Think Genomma Lab Internacional. de (BMV:LABB) Is An Interesting Stock
Sep 08Genomma Lab Internacional, S.A.B. de C.V.'s (BMV:LABB) Intrinsic Value Is Potentially 96% Above Its Share Price
Jun 10Is Genomma Lab Internacional. de (BMV:LABB) A Risky Investment?
May 24Should You Be Adding Genomma Lab Internacional. de (BMV:LABB) To Your Watchlist Today?
May 06Investors Who Bought Genomma Lab Internacional. de (BMV:LABB) Shares Five Years Ago Are Now Up 65%
Mar 13Genomma Lab Internacional. de (BMV:LABB) Has A Pretty Healthy Balance Sheet
Feb 19Do Its Financials Have Any Role To Play In Driving Genomma Lab Internacional, S.A.B. de C.V.'s (BMV:LABB) Stock Up Recently?
Feb 02Are Investors Undervaluing Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) By 42%?
Jan 15What Is The Ownership Structure Like For Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB)?
Dec 28Genomma Lab Internacional. de (BMV:LABB) Shareholders Have Enjoyed A 54% Share Price Gain
Dec 10
Shareholder Returns
| LAB B | MX Pharmaceuticals | MX Market | |
|---|---|---|---|
| 7D | -5.6% | -3.4% | -4.3% |
| 1Y | 90.7% | -26.8% | -14.1% |
Return vs Industry: LAB B exceeded the MX Pharmaceuticals industry which returned -26.8% over the past year.
Return vs Market: LAB B exceeded the MX Market which returned -14.1% over the past year.
Price Volatility
| LAB B volatility | |
|---|---|
| LAB B Average Weekly Movement | 4.5% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in MX Market | 6.0% |
| 10% least volatile stocks in MX Market | 2.6% |
Stable Share Price: LAB B has not had significant price volatility in the past 3 months compared to the MX market.
Volatility Over Time: LAB B's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 1,614 | Juan Marco Sparvieri | www.genommalab.com |
Genomma Lab Internacional, S.A.B. de C.V., together with its subsidiaries, provides pharmaceutical and personal care products primarily in Latin America. It develops, sells, and markets a range of branded products in the categories of anti-acne products, self-diagnosis, antibacterial, cream to improve the texture of scarred skin, shampoos, dandruff shampoos, soaps, razors, products to prevent hair loss, ointment for muscle pain, anti-fungal treatments for the relief of colitis, products to counter stress levels, anti-wrinkles, antacids, anti-ulcers, anti-flu, protection and sexual improvement, treatments against hemorrhoids, against varicose veins, osteoarthritis, ophthalmic medications, and infant nutrition. The company was incorporated in 1996 and is based in Mexico City, Mexico.
Genomma Lab Internacional, S.A.B. de C.V. Fundamentals Summary
| LAB B fundamental statistics | |
|---|---|
| Market cap | Mex$24.36b |
| Earnings (TTM) | Mex$1.60b |
| Revenue (TTM) | Mex$17.47b |
15.2x
P/E Ratio1.4x
P/S RatioIs LAB B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LAB B income statement (TTM) | |
|---|---|
| Revenue | Mex$17.47b |
| Cost of Revenue | Mex$6.36b |
| Gross Profit | Mex$11.10b |
| Other Expenses | Mex$9.50b |
| Earnings | Mex$1.60b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.70 |
| Gross Margin | 63.56% |
| Net Profit Margin | 9.18% |
| Debt/Equity Ratio | 59.1% |
How did LAB B perform over the long term?
See historical performance and comparisonDividends
3.1%
Current Dividend Yield23%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 02:28 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Genomma Lab Internacional, S.A.B. de C.V. is covered by 16 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Antonio Hernandez Velez Leija | Actinver Case de Bolsa, S.A. de C.V. |
| Benjamin Theurer | Barclays |
| Miguel Ulloa Suárez | BBVA Corporate and Investment Bank |